Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 10,787 Shares

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 10,787 shares of Zai Lab stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total value of $188,017.41. Following the completion of the transaction, the insider owned 52,391 shares of the company’s stock, valued at $913,175.13. The trade was a 17.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Zai Lab Stock Performance

ZLAB stock opened at $17.33 on Friday. The company’s 50 day moving average price is $20.37 and its 200 day moving average price is $29.21. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $16.82 and a fifty-two week high of $44.34. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -8.89 and a beta of 0.83.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Zai Lab had a negative return on equity of 25.83% and a negative net margin of 46.83%.The firm had revenue of $116.10 million during the quarter, compared to analysts’ expectations of $150.24 million. Equities analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Zai Lab has a consensus rating of “Moderate Buy” and an average target price of $56.35.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new stake in Zai Lab during the 3rd quarter worth $331,000. Acadian Asset Management LLC purchased a new position in shares of Zai Lab during the first quarter worth about $1,073,000. Cubist Systematic Strategies LLC increased its position in shares of Zai Lab by 29.0% during the first quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company’s stock worth $3,384,000 after purchasing an additional 21,026 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Zai Lab by 214.3% in the 1st quarter. Royal Bank of Canada now owns 13,771 shares of the company’s stock valued at $498,000 after purchasing an additional 9,390 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its holdings in shares of Zai Lab by 219.6% in the 1st quarter. Raymond James Financial Inc. now owns 125,967 shares of the company’s stock valued at $4,552,000 after purchasing an additional 86,547 shares during the last quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.